Home

1 min read

ASH Annual Meeting 2025 Day 3: Novel Antibody Therapies for High-Risk and Relapsed/Refractory Disease
Source: MMRF Published on: 2025-12-09
ASH Annual Meeting 2025 Day 2: New Data Show Lasting Responses with CAR T and Oral Therapies
Source: MMRF Published on: 2025-12-08
ASH Annual Meeting 2025 Day 1: Promising Results Across the Myeloma Spectrum
Source: MMRF Published on: 2025-12-06
ASH Annual Meeting 2025: How the MMRF is Driving New Discoveries and Collaborations
Source: MMRF Published on: 2025-12-05
Lynozyfic (linvoseltamab-gcpt): Another Breakthrough for Patients With Relapsed or Refractory Myeloma
Source: MMRF Published on: 2025-12-01
Understanding AML vs. ALL: Navigating the complex field
Source: (no title) Published on: 2025-07-31
Solving for end-of-life care disparities
Source: (no title) Published on: 2025-07-30
How humor helped me with cancer
Source: (no title) Published on: 2025-07-29
What causes acute myeloid leukemia?
Source: (no title) Published on: 2025-07-28
Holding onto hope: Living with chronic lymphocytic leukemia
Source: (no title) Published on: 2025-07-24